Qiming Venture Partners Weekly | Top 10 Portfolio News Vol.08, 2026.3.10
Staying with you through milestone moments at Qiming Venture Partners portfolio companies
Editor's Note: In 2026, the Qiming Weekly has been upgraded and refreshed, with regular weekly updates featuring only ten select major developments from Qiming Venture Partners' portfolio companies, covering funding progress and breakthroughs.
Every step entrepreneurs take in the tide of technology and innovation deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in following the milestone moments of our portfolio companies.
Major Partnerships
01/
WeRide Deepens Strategic Partnership with Geely's Farizon Auto
Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD, 0800.HK) has signed a strategic partnership deepening agreement with Geely Farizon New Energy Commercial Vehicle Group ("Farizon Auto"), unveiled the new upgraded pre-installed mass-produced Robotaxi GXR, and announced plans to deliver 2,000 Robotaxi GXR units in 2026 for deployment in domestic and overseas markets, fully advancing toward a new stage of global large-scale commercial Robotaxi operations.
The upgraded pre-installed mass-produced Robotaxi GXR will officially roll off the production line in Q3 2026. This mass delivery plan marks a significant acceleration in WeRide's Robotaxi commercialization. As of January 2026, WeRide's global Robotaxi fleet has reached 1,023 units. With the gradual delivery of 2,000 additional vehicles, the company's global in-service Robotaxi fleet will exceed 2,600 units this year, steadily advancing toward its goal of building a global fleet of tens of thousands of vehicles by 2030.
Dr. Tony Han, Founder and CEO of WeRide, said: "This deepening of strategic partnership between WeRide and Farizon Auto marks our evolution from product collaboration to ecosystem win-win, and is also a major milestone in WeRide's journey toward global large-scale Robotaxi deployment. Leveraging our technical synergy and efficient mass production system, we will accelerate the commercial rollout of Robotaxi GXR in China, the Middle East, Southeast Asia, Europe, and other markets, bringing safer, more reliable, and more accessible autonomous mobility services to users worldwide."
02/
HONOR's First Embodied AI Humanoid Robot Featuring Hesai Technology LiDAR Makes Official Debut
Recently, at the 2026 Mobile World Congress (MWC) in Barcelona, Spain, global technology brand HONOR's first embodied AI humanoid robot made a stunning debut, electrifying the audience with a futuristic "coming-out" dance performance. Equipped with Hesai Technology's (NASDAQ: HSAI, 02525.HK) JT series LiDAR, the robot completed high-difficulty moves including congratulations gestures, handshakes, moonwalks, and even backflips, winning rounds of applause for its silky-smooth performance.
Hesai Technology's JT series LiDAR, with its widest global field of view and compact form factor, provides robots with 360° blind-spot-free 3D perception, making it the optimal sensor for robotic spatial awareness. Meanwhile, the JT series' lightweight design and high reliability perfectly match the structural requirements of embodied AI robots, making it the common choice of leading embodied AI robot makers.
As the best-selling miniaturized 360° LiDAR currently deployed on embodied AI robots, Hesai Technology's JT series LiDAR has surpassed 200,000 units in cumulative deliveries as of 2025, successfully applied in multiple embodied AI robot products, helping robots move from laboratories into millions of households.
03/
Boan Biotech and DeepWise Form Strategic Partnership
Boan Biotech and Qiming Venture Partners portfolio company DeepWise have officially formed a strategic partnership. The two parties will collaborate to build an AI for Science (AI4S)-driven innovation model integrating "scientific intelligent agents + AI-powered drug discovery platform + novel mechanism biologic innovation drug R&D," focusing on deep cooperation in Boan Biotech's antibody drug, antibody-drug conjugate (ADC), and T-cell engager (TCE) drug development, using AI technology to empower new drug R&D and help advance both development efficiency and innovation quality.
Per the agreement, leveraging Boan Biotech's rich drug development experience and mature industrialization capabilities in antibody drugs, ADCs, and TCE drugs, together with DeepWise's leading AI4S technology and intelligent platform capabilities, the collaboration will focus on four core directions: life modality large models to assist antibody drug development, computation-driven ADC drug development, accelerated TCE drug pipeline layout, and exploration of cutting-edge AI4S drug innovation scenarios.
Weijie Sun, CEO of DeepWise, said: "DeepWise is committed to driving the transformation of drug discovery from experience-led to intelligent design and industrialized generation, exploring predictable, scalable, and sustainably iterative drug development engineering pathways for the biopharmaceutical industry. This partnership with Boan Biotech represents a convergence of technology and industry. We look forward to deeply integrating AI4S technology with Boan Biotech's R&D platform to help significantly accelerate R&D efficiency and upgrade innovation quality in antibodies, ADCs, TCEs, and other areas, speeding the market launch of more high-quality innovative biologics to address unmet clinical needs."
04/
Insilico Medicine and TaiGen Biopharmaceuticals Achieve Partnership Milestone
Recently, Qiming Venture Partners portfolio company Insilico Medicine Insilico Medicine (03696.HK), a generative AI-driven clinical-stage biopharmaceutical technology company, announced that ISM4808, its chronic kidney disease (CKD) anemia innovative drug previously out-licensed to TaiGen Biopharmaceuticals, has achieved its first contractual milestone. TaiGen Biopharmaceuticals has successfully completed first-patient enrollment and dosing in this AI-driven PHD inhibitor Phase I clinical trial.
Since reaching the partnership, TaiGen Biopharmaceuticals has efficiently initiated Phase I clinical trial preparations. The Phase I trial now underway is a randomized, double-blind, placebo-controlled study comprising single ascending dose (SAD) and multiple ascending dose (MAD) portions, designed to evaluate the safety, tolerability, and pharmacokinetic characteristics of ISM4808 in healthy adults.
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, said: "The efficiency demonstrated by our partner TaiGen in achieving clinical enrollment and dosing less than three months after in-licensing the asset is impressive, reflecting the efficient translation model of 'AI early discovery + specialized clinical development' that significantly shortens the path from concept to clinic for innovative drugs. We look forward to favorable clinical results for ISM4808, bringing a new oral treatment option with greater clinical advantages to CKD anemia patients. ISM4808 was originally discovered through Insilico Medicine's Chemistry42 platform as a PHD-targeting candidate drug. Another asset under the same target, Garutadustat for inflammatory bowel disease, is being advanced independently by Insilico Medicine and completed first-patient dosing in its Phase II clinical trial in January 2026."
05/
Biren Technology Powers DeepLink Heterogeneous Inference Solution
Recently, Shanghai Artificial Intelligence Laboratory launched the DeepLink multi-vendor heterogeneous inference acceleration solution ("DeepLink Heterogeneous Inference Solution"), achieving for the first time mixed scheduling and collaborative inference across multiple chips from four domestic computing vendors including Qiming Venture Partners portfolio company Biren Technology (06082.HK). The release of the DeepLink Heterogeneous Inference Solution both explores a new path for nationwide intelligent computing interconnection and efficient activation of dispersed computing resources, and provides stable, flexible, efficient, and low-cost computing power support for the implementation of "AI+" initiatives.
Biren Technology adheres to the philosophy of "technology openness, industry collaboration, and standard co-construction," conducting in-depth exploration in heterogeneous mixed training, heterogeneous mixed inference, and other heterogeneous computing key technologies, promoting efficient integration of diverse computing power. At the end of 2024, Biren Technology achieved for the first time in the industry mixed training across four heterogeneous chip types; subsequently, under the promotion of the AI Industry Working Committee, it took the lead in establishing the Intelligent Computing Cluster Heterogeneous Mixed Training Working Group, and under the leadership of the National Information Technology Standardization Committee, formulated national standards for heterogeneous mixed training, and deeply participated in DeepLink cross-domain mixed training collaboration. During the 2025 World Artificial Intelligence Conference, Biren Technology achieved another breakthrough, completing for the first time heterogeneous mixed inference based on Biren Technology, NVIDIA, and other chips, and jointly releasing a heterogeneous computing collaboration white paper with China Telecom Group Co., Ltd. This year, Biren Technology's cooperation with Shanghai Artificial Intelligence Laboratory has further deepened with the launch of the new DeepLink Heterogeneous Inference Solution.
Product Launches
01/
Insta360 Releases Snap Phone Selfie Screen
Recently, Qiming Venture Partners portfolio company Insta360 (688775.SH) launched Insta360 Snap, an innovative mobile imaging accessory. With magnetic direct connection, real-time preview, and full-platform compatibility as its core advantages, the product enables users to easily capture portrait-quality shots and 0.5x ultra-wide dynamic shots with main-camera-level image quality, providing a more professional and portable solution for imaging creation — officially described as making the phone's rear camera "seeable and beautiful."
Insta360 Snap is compatible not only with native phone cameras but also seamlessly with mainstream photo editing and professional photography apps. Users can combine the high-definition quality of rear cameras with the filter and makeup effects of various apps to expand creative possibilities. To meet lighting needs across different scenarios, Insta360 has partnered with AMIRO, an expert in beauty optics, to co-develop a version equipped with a ring fill light. This version supports three color temperatures and five brightness levels for precise light control.**
Roborock A30 Pro Steam 2.0 Smart Wet-Dry Vacuum Launches
Recently, Qiming Venture Partners portfolio company Roborock (688169.SH) announced the launch of the new Roborock A30 Pro Steam 2.0 wet-dry vacuum. The product features Roborock's pioneering HyperStorm Wash technology, with 180°C active steam, super steam mode, and 90°C hot water floor cleaning, redefining deep cleaning standards. It is specifically designed to tackle grease, stubborn stains, bacteria, dust mites, and allergens on floors, delivering a more thorough home cleaning experience.
Beyond top-tier cleaning power, the Roborock A30 Pro Steam 2.0 demonstrates exceptional industrial design in user-friendly features. The unit supports 12.5cm ultra-thin flat lying, with a thickness even lower than common smartphones, enabling it to reach under beds, sofas, and other blind spots. With AI-powered bidirectional assist and 70° adaptive torque, whether pushing forward, pulling back, or turning left and right, elderly and female users can easily maneuver it. For pet households' hair challenges, the product features dual shark-tooth zero-tangle technology. 141 dense shark teeth actively intercept hair before it reaches the roller brush, with a second layer of seamless scraper catching fine hair debris, earning SGS certification capable of handling 2,000 50cm-long hairs without tangling.
R&D Progress
MicroPort EndoMed Establishes Asia-Pacific's First RIRS Training Center in Singapore
Recently, the "Miniaturization in Endourology: Innovations & Techniques in fURS, mPCNL & ECIRS" symposium hosted by MicroPort EndoMed was successfully held at TTSH Hospital in Singapore. On this occasion, MicroPort EndoMed's first RIRS Training Center in the Asia-Pacific region was simultaneously established in Singapore, marking the formal creation of a systematic RIRS training platform in the region.
The burden of stone disease continues to rise in the Asia-Pacific region, placing higher demands on efficient, safe, and standardized minimally invasive treatment solutions. The uneven level of technical expertise across the region also calls for more systematic training and exchange mechanisms. Smaller outer diameter, larger vision. This is not only a choice of technical direction but also a shared responsibility that MicroPort EndoMed undertakes for the industry and patients. The Singapore TTSH Workshop is just the starting point; the establishment of the Asia-Pacific's first RIRS Training Center represents a longer-term vision — making advanced minimally invasive technology a shared regional capability rather than the exclusive advantage of a few centers.
Technological Strength
HyperStrong HyperBlock III Energy Storage System Successfully Passes Large-Scale Burn Test
Recently, under the full witness of international authoritative certification body CSA, North American registered fire protection engineers (FPE), and strategic clients, Qiming Venture Partners portfolio company HyperStrong (688411.SH)'s flagship energy storage product — the HyperBlock III energy storage system — successfully passed a large-scale burn test. The test not only invited overseas clients to observe on-site but also, for the first time in the industry, live-streamed a large-scale energy storage system burn test globally in real time, with over 40 global strategic clients invited to witness online, fully demonstrating HyperStrong's strong confidence in the HyperBlock III energy storage system's outstanding fire-resistant design and efficient thermal insulation protection performance.
Dr. Hao Qian, CTO of HyperStrong, said: "Safety is the lifeline of the energy storage industry and the foremost criterion in HyperStrong's product R&D. Prior to this test, we had completed full-tier precise simulation calculations and burn characteristic verification from cells to modules, battery clusters, and complete cabin systems, systematically validating the system's fire resistance and thermal insulation design. HyperBlock III's passing of the large-scale burn test in one attempt fully reflects the company's full-chain, full-linkage safety design philosophy and is also the crystallization of our long-term commitment to high-safety, high-reliability energy storage technology innovation. This test aims to provide clients with 'beyond-standard' safety assurance, not only laying the foundation for HyperStrong's next-generation high energy density, high-safety energy storage system product R&D and design, but also securing a critical cornerstone for the future large-scale promotion and safe deployment of gigawatt-hour-level energy storage power stations."
UBTECH Selected as National-Level "Manufacturing Single Champion Enterprise"
Recently, Qiming Venture Partners portfolio company UBTECH (09880.HK), based on its "AI education robots" global market share advantage, R&D and manufacturing leadership, successfully passed the Ministry of Industry and Information Technology review to receive the "National-Level Manufacturing Single Champion Enterprise (2025-2027)" honor. This top honor in the manufacturing sector represents a company's global leading position in a specific market segment and recognizes the company's R&D accumulation and technological innovation capabilities in the AI education field.
The "National-Level Manufacturing Single Champion Enterprise" list is determined through enterprise applications to local city governments, followed by selection by provincial industry and information technology departments and the Ministry of Industry and Information Technology, in accordance with the latest Manufacturing Single Champion Enterprise Recognition Management Measures ("Management Measures").
Per the Management Measures, the recognition focuses on evaluating enterprise performance in five aspects: specialized development, market competition, independent innovation, and operational management. Enterprises must have been deeply engaged in a specific niche for 5 years or more, with the market share of the applied product reaching the global top three. Product production technology or processes must be internationally advanced, with key performance indicators reaching internationally leading levels. Enterprises must possess high-level R&D institutions, with independent R&D investment intensity, independent intellectual property rights, and patent quantities leading the industry. The strict selection criteria are themselves proof of the certified enterprises' strength.
Previous Issues
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol. 07, 2026.3.4
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its establishment, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative enterprises, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions, with over 80 companies recognized as industry-leading unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Sinocelltech (688520.SH), Insilico Medicine (03696.HK), Hepaloc Therapeutics, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.